Demarin

Quick links to important sections

Demarin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demarin

Demarin is a brand name for a prescription pharmaceutical preparation whose active substance is Oxaprozin, a single-component chemical compound.

Property Description
Active ingredient Oxaprozin
Form Oral Solid (Tablet/Caplet)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Anti-inflammatory, Analgesic, Antipyretic
Origin Synthetic (Propionic acid derivative)

What Type of Medicine is Demarin (Oxaprozin)?

Demarin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging specifically to the propionic acid derivative subgroup. This classification confirms that the medication is designed to reduce pain and inflammation without relying on corticosteroid hormones.

Oxaprozin's crucial and differentiating property is its long elimination half-life, which can extend over 50 hours. This feature allows for a once-daily dosing regimen, which simplifies long-term treatment for patients managing chronic conditions.


Composition and Form: What is Demarin Made of?

The medication is composed solely of the active ingredient, Oxaprozin, combined with inert excipients necessary for formulating the product. Demarin is provided as an oral solid dosage form, typically a film-coated tablet or caplet, intended for systemic administration.

As an NSAID, Oxaprozin functions as a potent cyclooxygenase inhibitor, blocking the production of prostaglandins—the chemical messengers that promote pain and inflammation. Its efficacy in managing inflammatory symptoms is established.


What is the General Purpose of Demarin?

The core purpose of Demarin is to exert three integrated physiological effects: anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) properties. This combined action helps to alleviate the primary symptoms of chronic inflammatory processes, such as pain, swelling, and stiffness.

Regulatory References

  1. Oxaprozin: MedlinePlus Drug Information

What side effects are possible with Demarin?

Possible Side Effects and Safety Information

The official safety profile for Demarin (Oxaprozin), a Nonsteroidal Anti-inflammatory Drug (NSAID), is structured around common adverse reactions and serious class-wide risks documented in regulatory labeling.


Serious Adverse Reactions and Class Risks

Regulatory documents highlight two major safety concerns, which may occur at any time during treatment and may be fatal. These risks may also increase with the duration of use:

  • Serious Gastrointestinal Events: Including bleeding, ulceration, and perforation of the stomach or intestines.
  • Serious Cardiovascular Thrombotic Events: Including myocardial infarction (MI) and stroke.

Commonly Documented Adverse Effects

Adverse reactions are classified by System-Organ Class. Effects on the Gastrointestinal System are frequently reported. Reactions listed as Common (3% incidence in clinical trials) include dyspepsia, nausea, constipation, diarrhea, headache, dizziness, and rash. The medication may also lead to fluid retention and edema.


Population-Specific Safety Notes

Older adults are at a greater risk for serious gastrointestinal and renal adverse events. Furthermore, Oxaprozin is contraindicated in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Use is also not recommended in patients with advanced kidney disease.


Restrictions and Limitations

Oxaprozin is contraindicated for treating pain in the setting of coronary artery bypass graft (CABG) surgery and in patients who have experienced allergic-type reactions after taking aspirin or other NSAIDs. The medication, like other NSAIDs, can contribute to the new-onset or worsening of hypertension and may mask signs of infection and fever.

Overdose and Emergency Response

Overdosage with this Nonsteroidal Anti-inflammatory Drug (NSAID), Oxaprozin, primarily presents with documented symptoms affecting the gastrointestinal and central nervous systems. Officially recorded clinical manifestations following acute overdosage typically include epigastric pain, nausea, vomiting, lethargy, and drowsiness.

The official regulatory labeling mandates that individuals experiencing a suspected acute overdosage must seek immediate medical attention. This action is required due to the documented potential for severe or life-threatening outcomes, which are considered rare but include acute renal failure, coma, convulsions/seizures, gastrointestinal bleeding, hypertension, and respiratory depression. Emergency help must also be sought if an anaphylactoid reaction occurs.

The established management approach for an Oxaprozin overdosage is symptomatic and supportive care. This intervention is critical because the regulatory information confirms that no specific antidote is known for this substance. Furthermore, due to the drug’s high degree of protein binding, it is not significantly removed from the body by standard procedures such as hemodialysis. Gastric decontamination, such as the administration of activated charcoal, may be considered by medical professionals, particularly following large overdosages exceeding typical therapeutic limits.

Therapeutic Uses of Demarin

What Demarin Treats: Main Uses and Benefits

This medicine is used for the symptomatic management of conditions associated with inflammatory and pain responses. It is indicated for the management of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA).

The core therapeutic benefit is applied in addressing symptoms related to heightened physiological activity that may become intense or disruptive, specifically pain, joint stiffness, and swelling. It is also commonly used to help with symptoms related to systemic imbalance, such as fever associated with conditions involving inflammatory or irritative processes.

Applied across domains where additional symptomatic support is needed, this medicine generally helps to ease the overall symptom burden associated with persistent diseases. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as acute flares of chronic arthritis or episodes of acute gouty arthritis. This offers symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Supports management of Morning Stiffness By addressing rigidity and stiffness, this medication provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability.

Regulatory References

  1. Label: OXAPROZIN tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Demarin (Oxaprozin) eligibility is strictly defined by regulatory criteria, encompassing specific contraindications and conditional use requirements. Use is permitted only for adults with Osteoarthritis and Rheumatoid Arthritis, and for children 6 to 16 years of age with Juvenile Rheumatoid Arthritis.

Populations Excluded from Use (Contraindicated)

Use is absolutely prohibited for patients with:

  • Known hypersensitivity to oxaprozin or a history of allergic reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs.
  • Treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnant women starting at 30 weeks gestation (third trimester).

Conditional Use and Age Rules

Population Category Eligibility Status (Official Wording)
Children < 6 years Safety and effectiveness have not been established.
Advanced Renal/Cardiac Disease Use must be avoided unless benefits outweigh the risk of worsening the condition.
Geriatric (65+ years) Caution should be exercised due to increased sensitivity and risk.
Severe Hepatic Dysfunction Use requires caution.
Lactation Requires weighing potential benefits against risks to the infant.

Regulatory bodies classify these restrictions based on established risk profiles in vulnerable groups or conditions like organ impairment and advanced age.

What should I know about interactions with other medicines?

Demarin Interactions with other medicines and products

The regulatory information for Oxaprozin defines interactions based on the potential for combined toxicities and documented changes in drug exposure.

Interaction Restrictions and Exposure Changes

Interaction Category Interacting Substances Official Restriction/Outcome
Not Recommended Analgesic-dose Aspirin, other NSAIDs, Salicylates Use is not generally recommended due to compounding the risk of gastrointestinal toxicity and bleeding.
Exposure Modification Lithium, Methotrexate, Digoxin Oxaprozin reduces the renal clearance of these substances, leading to officially documented elevations in their plasma concentrations.

Pharmacodynamic and Timing Constraints

Oxaprozin exhibits a synergistic effect on bleeding when co-administered with Warfarin and other antiplatelet drugs, SSRIs, SNRIs, and Corticosteroids. This effect is associated with an increased risk of GI ulceration as stated in the label.

The medicine may also diminish the therapeutic effect of several cardiovascular and renal medicines, including ACE inhibitors, ARBs, Beta-Blockers, and Diuretics. In elderly, volume-depleted, or renally impaired patients, the combination with ACE inhibitors or ARBs carries an officially noted greater risk of acute renal function deterioration.

A specific administration timing rule applies to Pemetrexed; the long half-life of Oxaprozin requires avoidance beginning at least 5 days before and continuing through two days after Pemetrexed administration to mitigate toxicity risk. Additionally, alcohol increases the risk of gastric irritation, and food reduces the rate of Oxaprozin absorption, though the total amount absorbed remains unchanged.

Mechanism of Action

Enzymatic Suppression of Inflammatory Mediators

The drug acts as a non-selective competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This action suppresses the synthesis of prostaglandins from arachidonic acid, engaging a mechanism that interferes with pathways associated with heightened physiological responses. . This suppression of mediator synthesis is the initial molecular step that shapes the systemic reduction in prostaglandin-mediated biological responses.


Dual Action on Afferent Nerve Responses and Thermoregulation

The resultant reduction in prostaglandins affects two distinct systems. Peripherally, it reduces the sensitization of nociceptive nerve fibers, limiting the impact of excessive mediator activity on peripheral afferent nerve responses. Centrally, the mechanism engages pathways that reset the elevated hypothalamic temperature set-point, leading to predictable physiological adjustments that result in the normalization of the hypothalamic set-point.


Modulation of Renal Uric Acid Clearance

Beyond the primary COX-inhibitory mechanism, Oxaprozin possesses a unique secondary function that directly alters transport systems within the renal tubules that mediate waste elimination. This action is relevant in systems where modulation of solute concentration is required, specifically increasing the renal clearance of uric acid.

Dosage and Administration Information

How to Use Demarin (Oxaprozin)

Demarin is administered via the oral route (by mouth) and is characteristically used in a once-daily regimen due to the active substance, Oxaprozin, possessing a long elimination half-life. This administration pattern supports continuous management of chronic conditions.


Dosing and Administration

Standard administration parameters for this medication are as follows:

Feature Standard Instruction
Standard Adult Dose 1200 mg once daily for Rheumatoid Arthritis and Osteoarthritis.
Maximum Daily Dose 1800 mg per day (or 26 mg/kg, whichever is lower).
Intake Conditions Is typically taken with food or milk and a full glass of water to ensure proper administration.
Frequency Pattern Once daily (O.D.) is the standard, though the maximum dose may be administered in divided doses.

Population-Specific Dosing Rules

Dose adjustments are utilized based on patient characteristics to define the lowest effective dose for prolonged use:

  • Pediatric Use (JRA): The dosage is determined by weight, generally 10–15 mg/kg once daily.
  • Low Body Weight/Geriatric: Treatment should be initiated at the lower end of the dosing range, such as 600 mg once daily, for patients weighing less than 50 kg or in older adults.
  • Renal Impairment: Patients with severe renal impairment or on dialysis must begin therapy at 600 mg once daily. Doses can be increased cautiously with close monitoring, but should not exceed 1200 mg daily for this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Demarin (Oxaprozin)

Evidence for Use in Osteoarthritis (OA) Symptomatic Management

Research was evaluated in Randomized Controlled Trials (RCTs) (studies where participants are randomly assigned to groups) exploring how symptoms change over time for Osteoarthritis (OA). Researchers used these trials to examine patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort. They monitored outcomes related to functional imbalance, such as outcomes reflecting daily functioning or activity level.

Active-controlled trials described similar patterns related to symptom measurements compared to the reference NSAIDs used in the research setting. Long-term outcomes and the durability of measured symptomatic changes beyond six months are not fully established by dedicated, large-scale controlled research. Furthermore, existing studies provide limited insight into whether the medicine has any effect on the underlying structural progression of the disease, which is not the primary focus of the research.


Evidence for Use in Rheumatoid Arthritis (RA) Symptomatic Management

Demarin was evaluated in extensive multi-center Randomized Controlled Trials (RCTs) in research contexts involving fluctuating or unstable symptoms related to Rheumatoid Arthritis (RA). Studies explored outcomes related to physical discomfort and outcomes capturing phases of heightened symptom activity. Key outcomes linked to inflammatory or irritative states were studied, including objective measures like the count of tender and swollen joints, as well as the duration of morning stiffness.

As part of the evidence review, it was noted that the majority of controlled trial evidence for RA is short- to intermediate-term, typically lasting up to six months. Studies primarily focused on outcomes related to systemic or functional imbalance and were not designed to assess long-term outcomes related to disease modification.


Evidence in Pediatric Patients: Juvenile Rheumatoid Arthritis (JRA)

Research on Demarin for Juvenile Rheumatoid Arthritis (JRA) included active-controlled clinical trials and specialized studies focusing on how the medicine is processed by the body (pharmacokinetic studies) in children. The research so far indicates that studies monitored changes in the signs and symptoms of arthritis in the 6–16 age group during the study periods. Data for certain groups remain insufficient; studies are lacking for children younger than six years of age.

Key Studies & References

  1. OXAPROZIN tablet - Label Information for Professional Use (NDA 18-841)
  2. A critical assessment of oxaprozin clinical profile in rheumatic diseases - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Demarin (FAQ)


Q: Does Demarin work right away?

A: Official prescribing information indicates that symptomatic relief may begin within the first week of use. However, it is noted that it may take several weeks of regular administration to feel the full intended effects of the medicine.


Q: How long does it take for Demarin to start having an effect?

A: According to regulatory documents, the initial effects may be noticed within one week of starting treatment. For the continuous management of chronic conditions, full therapeutic effects may take several weeks to be fully established.


Q: Can Demarin make me feel tired or drowsy?

A: Regulatory documents list nervous system effects, including somnolence (drowsiness) and sedation, as documented adverse reactions. This is considered a possible side effect of the medicine.


Q: Can Demarin affect my ability to drive?

A: Official label information notes side effects such as dizziness and drowsiness. Label information indicates that caution is necessary when performing potentially hazardous activities, such as driving or operating heavy machinery, until an individual knows how the medicine affects them.


Q: Does Demarin interact with alcohol?

A: Regulatory information notes that combining the medicine with alcohol increases the documented risk of gastric irritation. This increase in risk is related to potential gastrointestinal issues.


Q: What if I have liver problems? Can I still use Demarin?

A: Official prescribing information indicates that the medicine requires caution when used in patients with severe hepatic dysfunction (severe liver problems). This information is used by healthcare providers when considering treatment.


Q: Is Demarin safe for older adults?

A: Official documents state that caution should be exercised when the medicine is used in older adults (65 years and older). This is due to an officially noted increased risk for serious gastrointestinal and renal adverse events in this population.


Q: Is Demarin the same as [Drug X, a competitor/similar drug]?

A: Demarin is a brand name for the medicine containing the single active ingredient Oxaprozin. It is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), which is a broad class of medicines that includes other drugs for similar conditions.


Q: Is Demarin considered a long-term treatment?

A: The drug is used for the continuous management of chronic conditions like arthritis. However, official warnings note that the risk of serious cardiovascular and gastrointestinal events may increase with the duration of use.


Q: What if I feel better—do I still need to take Demarin?

A: Official patient information states that for the management of continuing chronic conditions, the medicine must be taken regularly as directed by a healthcare professional. Regulatory documents state that any changes to the regimen should be discussed with a healthcare professional.


Q: How long has Demarin been on the market?

A: The active ingredient in Demarin, Oxaprozin, received its Initial U.S. Approval in 1992, according to official drug history records.


Q: Are there any long-term side effects associated with Demarin?

A: Official warnings note that the risk of serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal events (like bleeding) may increase with the duration of use.


Q: Does Demarin make you more sensitive to the sun?

A: Regulatory documents list photosensitivity or skin sensitivity to sunlight as a documented adverse reaction. This means the skin may react more strongly to sun exposure.


Q: Can Demarin affect my sleep pattern?

A: Official documents list insomnia (difficulty sleeping) and disturbance of sleep as documented adverse reactions that have been reported.


Q: If I miss a dose of Demarin, what happens?

A: If a dose is missed, regulatory information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory advice is to skip the missed dose and not take a double dose.


Q: Can I take Demarin if I am already taking over-the-counter pain relief?

A: Official interaction studies note that the co-administration of Oxaprozin and acetaminophen (a common OTC pain reliever) resulted in no statistically significant changes in drug parameters. This finding applies specifically to the co-administration with acetaminophen, and other pain relievers may require separate review.


Q: Can children or teenagers use Demarin?

A: Regulatory documents list approved use for children aged 6 to 16 years for Juvenile Rheumatoid Arthritis. The adult dosage is also stated in regulatory documents to be for adults and individuals 16 years of age and older.


Q: What if I accidentally take too much Demarin?

A: Symptoms following acute overdosage are typically limited to effects such as lethargy, drowsiness, nausea, vomiting, and epigastric pain (stomach discomfort). Official documents state that management typically involves symptomatic and supportive care.


Q: What does Demarin look like?

A: According to official product information for the 600 mg dose, the tablet is described as a white, capsule-shaped, biconvex, film-coated tablet that is scored.


Q: Can Demarin change my mood?

A: Official documents list potential nervous system adverse effects, including anxiety and depression, which have been reported in postmarketing experience. These documented effects are part of the medicine's full adverse reaction profile.


Q: Does Demarin cause weight gain or loss?

A: Official documents commonly report fluid retention and edema (swelling) as a side effect. Reports of unusual weight gain and weight loss are also listed in postmarketing surveillance.


Q: Can I crush or split the Demarin tablet?

A: Official administration instructions specify that the tablet should be swallowed whole. It is explicitly stated in regulatory information that it must not be broken, crushed, divided, or chewed.


Q: Is there a generic version of Demarin available?

A: Official drug databases and labeling exist for the active ingredient under the generic name Oxaprozin, in addition to the brand name products, indicating generic versions are available.


Q: Why does Demarin sometimes cause a metallic taste?

A: Official postmarketing reports include an alteration in taste as a documented adverse reaction. A metallic taste is one specific way this altered sense of taste may be described.


Q: Do official documents mention anything about Demarin affecting fertility?

A: Official labeling states that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including this medicine, are associated with reversible infertility. The regulatory label indicates that withdrawal of the medicine is a factor to be considered in women who are experiencing difficulties conceiving.


Q: What happens if I take Demarin with certain foods?

A: Official prescribing information indicates that taking the medicine with food reduces the rate of absorption of the medicine. However, the total amount of medicine absorbed by the body remains unchanged.


Q: Is it normal to feel a tingling sensation after starting Demarin?

A: Official documents list paresthesia as a documented nervous system adverse reaction. Paresthesia is a medical term for a sensation often described as tingling or pricking.


Q: Does the FDA or EMA have a special alert about Demarin?

A: The medicine carries a Boxed Warning in official labeling. This warning concerns the documented serious risks of cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal events (like bleeding or perforation).

How should Demarin be stored and disposed of?

How to Store and Dispose of Demarin?

Official regulatory guidelines dictate specific storage and disposal requirements to ensure product quality and safety.


Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (e.g., 20°C to 25°C). Do not freeze.
Protection Keep protected from light and excessive moisture.
Packaging Keep the medicine in its original container with the lid securely closed.

Handling and Disposal

Child Safety: It is mandatory to store Demarin out of the sight and reach of children.

Disposal: Unused or expired Demarin must not be disposed of in household trash or poured down a drain. Follow official local regulatory procedures, such as drug take-back programs, for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Demarin found in:

A-Z Index: